Exact Sciences Shareholders Approve Merger with Abbott, Merger to Move Forward

Exact Sciences Corp. (EXAS) shareholders have approved the proposed merger with Abbott Laboratories, with 67.56% of shares represented in person or by proxy. Abbott Laboratories will acquire EXAS for $105 per share in cash, a transaction valued at approximately $21 billion. Completion of the merger remains subject to customary closing conditions, including regulatory approvals.